Screener
Bristol-Myers Squibb BMY Ireland — Other
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments.
The source filing: Bristol-Myers Squibb’s 10-K, filed February 11, 2026.
- Filed
- Feb 10, 2026, 7:00 PM EST
- Fiscal year
- FY2025
- Accession
- 0000014272-26-000004
| Dollars in millions | % of Earnings Before Income Taxes / 2025 |
|---|---|
| Ireland | |
| Statutory tax rate difference between Ireland and the U.S. | (390)% |
| Pillar Two | 37% |
| Other | 2% |
| Other foreign jurisdictions | 129% |
| U.S. Federal research-based credits | (152)% |
| Changes in valuation allowances | 84% |
| Nondeductible R&D charges | 290% |
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
FAQ
- What is Bristol-Myers Squibb's ireland — other?
- Bristol-Myers Squibb (BMY) reported ireland — other of $0 in Q4 2025.
- What does ireland — other mean?
- This metric represents miscellaneous tax adjustments or non-recurring items specifically attributed to the company's operations in the Ireland segment that do not fall into primary tax categories. It serves as a catch-all for minor reconciliation items that impact the local effective tax rate. Investors monitor this to identify any unusual or non-operational tax events that could distort the underlying profitability of the regional segment.
Ask your AI about Bristol-Myers Squibb's ireland — other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude